Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Maltose-binding protein (MBP) is a 42.5 kDa periplasmic protein primarily found in Gram-negative bacteria such as Escherichia coli, where it is encoded by the malE gene (UniProt: P0AEX9). It serves as a crucial component of the maltose/maltodextrin transport system, binding these carbohydrates with high affinity and delivering them to the MalFGK2 ABC transporter for translocation across the cytoplasmic membrane (PubMed: 16452471). Beyond its transport role, MBP acts as a primary chemoreceptor that triggers bacterial chemotaxis toward maltose by interacting with the Tar protein (PubMed: 6270604). In biotechnology and molecular biology, MBP is widely utilized as a fusion partner to enhance the solubility and facilitate the proper folding of recombinant proteins (PubMed: 10445867). While not a primary therapeutic target for human diseases, its essential role in bacterial survival makes it a subject of interest in antimicrobial research. It is also frequently employed as a carrier protein in vaccine development to increase the immunogenicity of antigens (PubMed: 11544354).
Not applicable as there are no approved drugs targeting this protein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Maltose-binding protein (MBP) (MBP).